Medicare covers TriClip | Pascal system linked to key benefits after M-TEER, T-TEER | Pairing SAVR with other heart surgeries

CMS has finalized a new national coverage determination for T-TEER, sometimes known as transcatheter tricuspid valve repair. Abbott's TriClip is the only device approved by the FDA for T-TEER, but other treatment options are under development.

The tricuspid valve has been at the center of several key policy shifts in recent years. In fact, Medicare now covers both T-TEER and TTVR when performed with FDA-approved devices. We spoke to interventional cardiologist Jason H. Rogers, MD, to learn more about how this momentum has impacted patient care. 

The interventional device, designed to perform both M-TEER and T-TEER, is at the center of two new studies published in EuroIntervention.

The minimally invasive operation, known as AVATAR, is performed through a small incision in the patient’s neck.

When older patients undergo SAVR with concomitant procedures, it increases their short- and long-term risks of mortality. Should this influence care teams to consider more transcatheter treatments? 

Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.

The Siegel TAVR valve includes no nickel or cobalt. In fact, its frame was built using special alloys specifically developed by MiRus.